Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of lanifibranor in adults with non-cirrhotic NASH and F2/F3 fibrosis
CTR20232876Phase 3Active
- Sponsor
- Inventiva
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Inventiva. Started Dec 2023; status: active.
02
Drugs
lanifibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20232876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232876.